Wednesday, 29 March 2023 to Thursday, 30 March 2023

Integrated Drug Discovery and Early Development Services in Age-related diseases


D Schnerwitzki1; D Lauer1; N Liaw1; E May1
1 Nuvisan ICB GmbH, Germany


The trend towards higher life expectancy observed over the past decades is accompanied by an increasing number of patients with various diseases that often affect the cardiovascular, nervous, and metabolic systems. Since this has become a challenge for any modern health system, a continuous demand to develop new treatments is emerging. As aging is affecting the whole body, research and development of new therapies require flexible approaches looking at various organs and tissues and thereby integrating conventional and modern state-of-the-art techniques. Based on our extensive pharmaceutical research expertise, Nuvisan ICB GmbH provides comprehensive in vivo and in vitro platforms to support drug discovery programs for various therapeutic areas. Moreover, we build model systems to identify and validate novel drug targets in age-related diseases and beyond. These activities are supported by our in-house expertise in induced pluripotent stem cells (iPSCs) that allow the development of personalized therapies, as well.

Hosted By


The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis